VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Sequencing BCMA-targeted agents in multiple myeloma

Salomon Manier, MD, PhD, Lille University, Lille, France, discusses the feasibility and efficacy of sequencing BCMA-targeted agents in multiple myeloma. Whilst it has been shown that it is possible to sequence BCMA-targeted agents, response rates (RR) are lower when patients that have been exposed to an anti-BCMA agent are treated with a second BCMA-targeted drug. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter